Investment & Operations Platform for Innovative Therapies

Transforming Scientific Innovation into Pharma-Ready Therapeutic Solutions

Between today and 2030, the expected loss of patent exclusivity will impact roughly 200 medicines — around 70 of them blockbusters — putting €250–300+ billion in annual revenues at risk. As internal R&D productivity declines, large pharmaceutical companies are increasingly dependent on externally sourced innovation, with total M&A deal value growing from roughly €191B in 2024 to roughly €240B in 2025.

Many promising therapeutic candidates fail to achieve meaningful clinical and strategic milestones due to suboptimal development execution. Current start-up development models fall short in supporting laboratory-sourced innovation to extend and translate beyond the lab, into clinical research, regulatory pack development, and eventually in-market therapy.

THERAVION bridges the gap between breakthrough science and building clinical research and development-ready assets — combining capital, operational and R&D guidance, and translational expertise in a single integrated platform.